stockrow
Friday 6 November 2026
Export LSTA’s income statement to Excel — free account
Lisata Therapeutics, Inc.
LSTA Healthcare Biotechnology
Lisata Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170,000.00, down 83.0% from fiscal 2024.
- Revenue
- −98.3%
- EPS
- +40.7%
- Free cash flow
- +33.0%
Quarter to June 2026, against a year earlier
1.02
0.03
+3.03%
Follow LSTA
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(72.17%) | (75.53%) | (91.41%) | (101.66%) | |
| (60.85%) | (62.89%) | (75.98%) | (80.81%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(107.12%) | (113.22%) | (152.51%) | (181.85%) | |
Average Days of Receivables |
0.00 | 0.00 | — | — | |
Free Cash Flow per Share |
(1.98) | (1.84) | (1.51) | (1.35) | |
Free Cash Flow |
(17.28) | (15.98) | (13.63) | (12.32) | |
Capital Expenditures |
(0.05) | (0.03) | — | — | |
| Other line items | |||||
Cash ROIC |
(47.85%) | (52.29%) | (57.43%) | (66.85%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | (0.27) | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 52.23% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 68.53% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 8.06% | 0.00% | 0.00% | |
Operating CF/Net income |
0.94 | 0.96 | 0.83 | 0.84 | |
Depreciation/Fixed assets |
0.82 | 3.94 | 4.44 | 3.57 | |
Capex/Depreciation |
(3.00) | (0.39) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 1.75 | 0.00 | 0.00 | |
Operating CF per Share |
(1.97) | (1.84) | (1.51) | (1.35) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates · fundamentals updated 26 Oct 2026